Dramatic advances in the diagnosis and treatment of influenza in Japan have been made in recent years [1] . Most patients with an influenza-like illness are now tested with rapid diagnostic tests and, if the results are positive, they are treated with the neuraminidase inhibitor oseltamivir. The rapid influenza diagnosis kit was introduced in Japan in time for the 1999-2000 epidemic; it was estimated that ∼17 million people (14% of Japan's population) may have been tested with it during the 2004-2005 influenza season [2] . The diagnostic kits used in Japan are capable of detecting influenza A or B separately; thus, Japanese clinicians prescribe oseltamivir with the knowledge of whether their patients have been infected with the influenza A or B virus.
Japan currently has the highest amount of neuraminidase inhibitor use in the world. More than 70%-80% of the total oseltamivir prescribed throughout the world every year is used in Japan [2] . Oseltamivir therapy is now routine in Japan, and almost all children with influenza are treated with oseltamivir, regardless of their underlying condition. [3] . Approximately 55% of the influenza viruses isolated were influenza B/Shanghai-like stains, making it the largest influenza B epidemic to occur to date after the introduction of oseltamivir in Japan during the 2000-2001 season. During the epidemic, many Japanese physicians claimed that children with influenza B often had a persistently high fever despite receiving oseltamivir therapy within 48 h of the onset of illness and, thus, that influenza B viruses may have become resistant to oseltamivir. This was a clinically serious problem, because in children, influenza B is as severe an illness as influenza A and is a frequent cause of pediatric hospitalizations during the winter influenza season [4, 5] . Moreover, it was reported that oseltamivir might be less effective against influenza B, mainly in adult patients [6] .
We have compared the effectiveness of oseltamivir against influenza A (H3N2) and influenza B on the basis of the duration of the febrile period, because high and prolonged fever is one of the most important symptoms of influenza virus infection in children [7] , and because it can be objectively assessed. We also determined the IC 50 for B viruses that were isolated. pediatric departments of our hospitals. All patients presented with a temperature 138.0ЊC within 48 h after the onset of a febrile illness. They were tested with rapid diagnostic tests (in most cases, Espline Influenza A&B-N; Fujirebio), and were diagnosed with influenza A or B before the start of oseltamivir therapy. Diagnoses were confirmed by virus isolation; 103 influenza A (H3N2) and 321 influenza B viruses were isolated.
PATIENTS AND METHODS

Patients
In approximately three-fourths of the patients who were observed, oseltamivir was prescribed in weight-based unit doses, taken twice daily for 5 days (for patients who weighed !15 kg, 60 mg/day; patients 15-23 kg, 90 mg/day; patients 23-40 kg, 120 mg/day; and patients 140 kg, 150 mg/day). The remaining patients were treated with oseltamivir, 4 mg per kg per day for 5 days.
Parents were instructed to take their children's temperatures twice daily-in the morning and in the evening. These temperature values were recorded on a fever record sheet that we prepared, which was returned to us on the day of the final visit. When a patient's temperature decreased to !37.5ЊC and remained there for 2 more measurements, we considered the temperature to have returned to normal. If a patient's temperature decreased to !37.5ЊC once and remained !37.5ЊC for the next 2 measurements (∼24 h), but later increased to 137.5ЊC, we considered the patient to have a biphasic fever pattern.
Because we had no cases for comparison of influenza A that was not treated with oseltamivir for the total febrile period (because oseltamivir is now routine therapy for influenza in Japan), we analyzed the clinical course of patients who had influenza A (H3N2) during the 2001-2002 epidemic who were not treated with antiviral agents [8] . Their diagnosis was confirmed by virus isolation. The control subjects for influenza B were those who did not receive oseltamivir during the 2004-2005 epidemic, because their rapid test results were negative at the first visit (influenza B viruses were isolated from these patients after the first visit, however).
METHODS
Virus isolation and titration.
Clinical specimens (throat swabs or nasal swabs) collected during the 2004-2005 influenza season that were shown to be virus-positive by rapid diagnostic kits were stored at Ϫ80ЊC until virus isolation. Madin-Darby canine kidney (MDCK) cells (for type A viruses) and MDCK cells overexpressing the b-galactoside a2,6-sialyltransferase I (ST6Gal I) gene were maintained at 37ЊC in minimal essential medium (MEM) containing 5% newborn calf serum and antibiotics under a 5% CO 2 atmosphere and used for viral isolation and plaque assay. MDCK cells overexpressing the ST6Gal I gene support clinical isolates of human influenza viruses better than MDCK cells do [9] .
Clinical samples possibly containing influenza viruses were incubated with the MDCK cells overexpressing the ST6Gal I gene for 3 days at 33ЊC in the presence of tosyl phenylalanine cholormethyl ketone-treated trypsin (0.5 mg/mL) in MEM containing 7.5% bovine serum albumin. They were then cultured in infection medium (7.5% bovine serum albumin, 0.5 mg/mL of trypsin, and 1% agarose in MEM). Viral subtypes were determined by conventional hemagglutinin and neuraminidase inhibition assays.
Sialidase sensitivity to oseltamivir. The sialidase sensitivity of influenza B viruses to oseltamivir was evaluated with a sialidase inhibition assay, as described previously [10] . Briefly, 2 -(4-methylumbelliferyl)-a-d-n-acetylneuraminic acid (MU-NANA; Sigma) at a final concentration of 0.1 mmol/L was used as a substrate. After mixing 10 mL of the virus dilution (predetermined to contain sialidase activity in the range of 800-1200 fluorescence units in this assay) and 10 mL of the NA inhibitor (0.01 nmol/L to 10 mmol/L) in a calcium and 2-[nmorpholino]ethanesulfonic acid (MES) buffer (33 mmol/L MES, 4 mmol/L CaCl 2 ; pH 6.0) and incubating at 37ЊC for 30 min, 30 mL of the substrate was added. The mixture was further incubated at 37ЊC for 60 min, and the reaction was stopped by adding 150 mL of 0.1 mol/L NaOH in 80% ethanol (pH, Informed consent was obtained orally from each child's parent or guardian, and it was recorded in each chart. Informed consent was also obtained from children 17 years of age who were able to understand the concepts and procedures of the protocol. This study was conducted with the approval of the ethics committees of our hospitals.
RESULTS
Total febrile period.
There was a significant difference in the mean duration of fever period between the study patients with influenza A (H3N2) who were treated with oseltamivir and the control subjects ( days vs. ).
The body temperature of 90.6% of patients with influenza A (H3N2) decreased to a normal level within 2 days after the start of oseltamivir therapy (table 1) , as opposed to only 62.2% of the patients with influenza B (
). Many patients with P ! .001 influenza B had a prolonged febrile illness that lasted 3-7 days after the start of oseltamivir. Biphasic fever was observed in 20.4% of the patients with influenza B who were treated with oseltamivir, but in only 3.1% of the patients with influenza A (H3N2) who were treated with oseltamivir ( ). P ! .001 Effectiveness of oseltamivir according to age. Table 2 shows patient age and the duration of fever after the start of oseltamivir therapy. The duration of fever in the patients with influenza B was significantly longer in young children (age range, 1-5 years; mean duration of fever, 2.37 days) than in older children (age range, 6-10 years [mean duration of fever, 1.97 days;
] and 11-15 years [mean duration of fever, 1.54 P p .013 days, ]). The difference in duration of fever between P p .006 patients with influenza B who were 6-10 years old and those who were 11-15 years old was not significant ( ). By P p .14 contrast, there were no significant differences in fever duration between age groups of patients with influenza A (H3N2).
Among children 1-5 years old and 6-10 years old, there were significant differences in the duration of fever between the patients with influenza A (H3N2) and the patients with influenza B ( (table 2) . By contrast, the difference in P ! .001 fever duration among children 11-15 years old between patients with influenza A (H3N2) and patients with influenza B was not significant ( ). P p .54 Although the duration of fever after the start of oseltamivir was longer in the influenza B group than in the influenza A (H3N2) group, the difference in children aged 11-15 years was not significant. Lower effectiveness of oseltamivir against influenza B was observed in younger children, especially in the 1-5-year-old age group. ). These results show that, in young children (age, 1-P p .30 5 years) vaccination was synergistically effective with oseltamivir in reducing fever duration in influenza B.
Effectiveness of oseltamivir and history of vaccination.
Virus shedding. Figure 1 shows changes in virus shedding in the throat after the start of oseltamivir therapy in 18 patients with influenza A (H3N2) (mean age, 5.89 years) and 39 patients with influenza B (mean age, 3.94 years). All patients were treated with a weight-based unit dose of oseltamivir, administered twice daily for 5 days. Before oseltamivir therapy (day 0), mean virus infectivity was similar in the influenza A (H3N2) group and influenza B group ( [ ] and 3.53 ‫ע‬ 0.74 n p 18 [ ], respectively; virus infectivity titers are 4.00 ‫ע‬ 1.18 n p 39 expressed as log 10 plaque-forming units/mL). After the start of oseltamivir therapy, virus titers in the specimens from the patients with influenza A (H3N2) decreased much faster than in the specimens from patients influenza B. Two days after the start of oseltamivir therapy, there was a significant difference in the mean virus titers between influenza A (H3N2) group and influenza B group ( [ ] and 0.61 ‫ע‬ 0.91 n p 14 2.84 ‫ע‬ 1.51 [ ], respectively; ). n p 27 P ! .001 IC 50 of oseltamivir carboxylate. We tested 192 influenza B viruses that were isolated from the patients described above prior to the initiation of oseltamivir treatment for sensitivity to oseltamivir carboxylate, the active form of oseltamivir phosphate. The mean IC 50 of oseltamivir by the sialidase inhibition assay was nmol/L, which is ∼250-fold less suscep-75.4 ‫ע‬ 41.7 tible to oseltamivir as influenza A (H3N2) viruses (0.3 ‫ע‬ 0.1 nmol/L) [10] . Three of 192 viruses had IC 50 values 1200 nmol/ L and, thus, may have been resistant to oseltamivir. If so, only 3 (1.6%) of the 192 patients who were tested had been infected by oseltamivir-resistant viruses; a detailed analysis of these oseltamivir-resistant viruses will be reported elsewhere.
Because we suspected that the lower clinical effectiveness of oseltamivir in patients with influenza B reflected decreased sensitivity of the influenza B viruses that were isolated in 2004-2005, we determined the IC 50 of earlier influenza B epidemic strains. However, there were no significant differences between the sensitivity to oseltamivir of influenza B isolates in the 2004-2005 epidemic and the earlier influenza B strains. Similarly, there was no significant difference between the Yamagata and the Victoria lineages (figure 2). 
DISCUSSION
Although oseltamivir has been thought to be equally effective against influenza A and B virus infections [11] [12] [13] [14] , the results of this study show that it is clinically much less effective, on the basis of duration of febrile illness after the start of oseltamivir therapy, against influenza B infection in children than it is against influenza A (H3N2) infection in children. Analyses performed according to age groups demonstrated lower effectiveness in younger children (age, 1-10 years), especially in children aged 1-5 years. There was no significant difference observed in the effectiveness of oseltamivir between patients with influenza A (H3N2) and patients with influenza B in older children (age, 11-15 years).
Lower effectiveness of oseltamivir against influenza B in young children was demonstrated not only by clinical data, but also by virus infectivity data (figure 1). Oseltamivir was not effective against influenza B viral shedding. Our data indicate that young patients with influenza B may be fully infectious until 3 days after the start of oseltamivir therapy.
We suspected that the sensitivity (measured as IC 50 ) of influenza B viruses to oseltamivir changed and became much lower during the 2004-2005 influenza season. However, because there were no significant differences in mean IC 50 values between influenza B viruses isolated from 1994 to 2005 (figure 2), we could not attribute the observed lower clinical effectiveness to a reduced sensitivity (IC 50 ) of influenza B viruses to oseltamivir.
Although we identified several influenza B viruses among our isolates that showed high IC 50 values against oseltamivir, and although some resistant viruses may circulate in the community, the lower clinical effectiveness against influenza B virus infection described here is unlikely to be attributable to virus resistance to the drug, because only 1.6% of the patients who were examined in this study shed viruses with IC 50 values 1200 nmol/L.
Comparison of the effectiveness of oseltamivir against influenza B between age groups revealed lower effectiveness in younger children and no significant difference in the effectiveness of oseltamivir against influenza A and the effectiveness of oseltamivir against influenza B in older children (age, 6-15 years). We observed a phenomenon in which the effectiveness of oseltamivir against influenza B increased with patient age (table  2) . Therefore, we believe that the clinical effectiveness of oseltamivir against influenza B is related to patient age or to their immune status.
Recent influenza B epidemics have been caused by influenza viruses of the Yamagata and/or Victoria lineages. The antigenic characteristics of these 2 lineages are totally different, and there is no cross-reactivity between their hemagglutination inhibition antibodies [15] . [3] , most young children 1-5 years old did not have immunity against the epidemic influenza B virus. Perhaps, then, oseltamivir is not fully effective against influenza B in children if they have not immunity against influenza B; this probably reflects the reduction in the sensitivity (IC 50 ) of influenza B viruses to oseltamivir, which are ∼250-fold less susceptible to oseltamivir than influenza A (H3N2) viruses. One piece of supporting evidence is that, during the 2004-2005 season, vaccination was synergistically effective against influenza B virus infection for reducing fever duration after the start of oseltamivir in young children 1-5 years old.
Although the IC 50 of influenza B virus to oseltamivir has been reported to be higher than that of influenza A (H3N2) [18] [19] [20] [21] [22] [23] , the differences have not been large: 0.45 nmol/L versus 8.5 nmol/ L [18] and 0.73 nmol/L versus 11.53 nmol/L [19] for influenza type A virus and influenza type B virus, respectively. However, although we followed the method of Gubareva et al. [24] and our IC 50 values for influenza A viruses were similar, for unknown reasons, our mean IC 50 value for influenza B viruses was higher than obtained by other investigators [18] [19] [20] [21] [22] [23] .
The limitations of this study should be recognized. It was an observational-not a randomized-study. Although parents were instructed to administer antipyretics (e.g., acetaminophen) only when their child's temperature increased to 138.5ЊC, the effect of antipyretic use on fever duration was unknown.
In conclusion, the effectiveness of oseltamivir against influenza B virus infection is influenced by the age or the immunity of the host-like that caused by influenza vaccine [25] -probably because of the low sensitivity of influenza B viruses to oseltamivir. Thus, oseltamivir is much less effective against influenza B virus infection in young children. We should reconsider the use of oseltamivir against influenza B infection in children, especially in young children. Increased dosage of oseltamivir or use of zanamivir are probable options for influenza B virus infection in children.
